Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group.

Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.

2.

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

Qin T, Jelinek J, Si J, Shu J, Issa JP.

Blood. 2009 Jan 15;113(3):659-67. doi: 10.1182/blood-2008-02-140038. Epub 2008 Oct 17.

3.

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP.

Blood. 2008 Aug 15;112(4):1366-73. doi: 10.1182/blood-2007-11-126227. Epub 2008 Jun 3.

4.

A parallel phase I/II clinical trial design for combination therapies.

Huang X, Biswas S, Oki Y, Issa JP, Berry DA.

Biometrics. 2007 Jun;63(2):429-36.

PMID:
17688495
5.

Effect of cytarabine and decitabine in combination in human leukemic cell lines.

Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP.

Clin Cancer Res. 2007 Jul 15;13(14):4225-32.

6.

DNA methylation as a therapeutic target in cancer.

Issa JP.

Clin Cancer Res. 2007 Mar 15;13(6):1634-7. Review.

7.

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, Büchner T, Berdel WE, Serve H, Müller-Tidow C.

Cancer Res. 2007 Feb 1;67(3):1370-7.

8.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B.

J Clin Oncol. 2006 Aug 20;24(24):3895-903.

PMID:
16921040
9.

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.

Teodoridis JM, Strathdee G, Brown R.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78. Review.

PMID:
15533764
10.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco].

PMID:
14673054
11.

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM.

Blood. 2004 Mar 1;103(5):1635-40. Epub 2003 Nov 6.

12.

Strategies for reversing drug resistance.

Fojo T, Bates S.

Oncogene. 2003 Oct 20;22(47):7512-23. Review.

PMID:
14576855
13.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF.

J Clin Oncol. 2002 May 15;20(10):2429-40.

PMID:
12011120
14.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization(WHO) international working group.

Blood. 2000 Dec 1;96(12):3671-4.

15.

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

Schröder JK, Kirch C, Seeber S, Schütte J.

Br J Haematol. 1998 Dec;103(4):1096-103.

PMID:
9886326
18.

Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation.

Mohandas T, Sparkes RS, Shapiro LJ.

Science. 1981 Jan 23;211(4480):393-6.

PMID:
6164095
19.
20.

Cellular differentiation, cytidine analogs and DNA methylation.

Jones PA, Taylor SM.

Cell. 1980 May;20(1):85-93.

PMID:
6156004

Supplemental Content

Support Center